Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Study Information
Alliance Study ID: CALGB 50803
NCT Study ID (ClinicalTrials.gov): NCT01145495
Alliance Committee: Lymphoma
Disease or Cancer Type: Lymphoma
Alliance Study Chair: Peter Martin
Status: COMPLETED
Study Description
This phase II trial studies how well lenalidomide and rituximab work in treating patients with previously untreated stage II, stage III, or stage IV follicular non-Hodgkin lymphoma. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving lenalidomide together with rituximab may kill more cancer cells.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information